- Home
- TRVI vs KALV Comparison
TRVI vs KALV Comparison
Compare TRVI & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- KALV
- Stock Information
- Founded
- TRVI 2011
- KALV N/A
- Country
- TRVI United States
- KALV United States
- Employees
- TRVI N/A
- KALV 270
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- KALV Health Care
- Exchange
- TRVI Nasdaq
- KALV Nasdaq
- Market Cap
- TRVI 725.7M
- KALV 796.4M
- IPO Year
- TRVI 2019
- KALV N/A
- Fundamental
- Price
- TRVI $7.01
- KALV $15.82
- Analyst Decision
- TRVI Strong Buy
- KALV Strong Buy
- Analyst Count
- TRVI 10
- KALV 9
- Target Price
- TRVI $19.35
- KALV $26.29
- AVG Volume (30 Days)
- TRVI 2.0M
- KALV 734.1K
- Earning Date
- TRVI 11-05-2025
- KALV 09-09-2025
- Dividend Yield
- TRVI N/A
- KALV N/A
- EPS Growth
- TRVI N/A
- KALV N/A
- EPS
- TRVI N/A
- KALV N/A
- Revenue
- TRVI N/A
- KALV N/A
- Revenue This Year
- TRVI N/A
- KALV N/A
- Revenue Next Year
- TRVI N/A
- KALV $221.95
- P/E Ratio
- TRVI N/A
- KALV N/A
- Revenue Growth
- TRVI N/A
- KALV N/A
- 52 Week Low
- TRVI $2.36
- KALV $7.30
- 52 Week High
- TRVI $8.78
- KALV $16.32
- Technical
- Relative Strength Index (RSI)
- TRVI 44.05
- KALV 71.16
- Support Level
- TRVI $7.09
- KALV $13.72
- Resistance Level
- TRVI $8.78
- KALV $13.96
- Average True Range (ATR)
- TRVI 0.43
- KALV 0.69
- MACD
- TRVI -0.07
- KALV 0.31
- Stochastic Oscillator
- TRVI 4.32
- KALV 99.15
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.